The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Sickle Cell Anemia Therapeutics Market Research Report 2025
Synopsis
Sickle cell disease (SCD) is a chronic, inherited blood disorder that impacts hemoglobin, a protein found in red blood cells (RBCs) that carries oxygen throughout the body. The disease is caused by a genetic mutation in the beta-chain of hemoglobin, which results in the formation of abnormal hemoglobin known as sickle hemoglobin (HbS).
The global Sickle Cell Anemia Therapeutics market was valued at US$ 3344 million in 2023 and is anticipated to reach US$ 9388.1 million by 2030, witnessing a CAGR of 15.7% during the forecast period 2024-2030.
Global Sickle Cell Anemia Therapeutics key players include Emmaus Medical, Addmedica, Gamida Cell, GlycoMimetics, etc.
Americas is the largest market, with a share about 55%, followed by Europe, and Middle East & Africa, both have a share over 35 percent.
In terms of product, Blood Transfusion is the largest segment, with a share over 35%. And in terms of application, the largest application is Child, followed by Adult.
This report aims to provide a comprehensive presentation of the global market for Sickle Cell Anemia Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Sickle Cell Anemia Therapeutics.
Report Scope
The Sickle Cell Anemia Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Sickle Cell Anemia Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Sickle Cell Anemia Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Emmaus Medical
Addmedica
Gamida Cell
GlycoMimetics
Pfizer
Novartis
Global Blood Therapeutics
Micelle BioPharma
Bluebird Bio
Prolong Pharmaceuticals
Modus Therapeutics
Sangamo Biosciences
Bioverativ
Imara
Ironwood Pharmaceuticals
Segment by Type
Blood Transfusion
Pharmacotherapy
Bone Marrow Transplant
Segment by Application
Child
Adult
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Sickle Cell Anemia Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Sickle cell disease (SCD) is a chronic, inherited blood disorder that impacts hemoglobin, a protein found in red blood cells (RBCs) that carries oxygen throughout the body. The disease is caused by a genetic mutation in the beta-chain of hemoglobin, which results in the formation of abnormal hemoglobin known as sickle hemoglobin (HbS).
The global Sickle Cell Anemia Therapeutics market was valued at US$ 3344 million in 2023 and is anticipated to reach US$ 9388.1 million by 2030, witnessing a CAGR of 15.7% during the forecast period 2024-2030.
Global Sickle Cell Anemia Therapeutics key players include Emmaus Medical, Addmedica, Gamida Cell, GlycoMimetics, etc.
Americas is the largest market, with a share about 55%, followed by Europe, and Middle East & Africa, both have a share over 35 percent.
In terms of product, Blood Transfusion is the largest segment, with a share over 35%. And in terms of application, the largest application is Child, followed by Adult.
This report aims to provide a comprehensive presentation of the global market for Sickle Cell Anemia Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Sickle Cell Anemia Therapeutics.
Report Scope
The Sickle Cell Anemia Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Sickle Cell Anemia Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Sickle Cell Anemia Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Emmaus Medical
Addmedica
Gamida Cell
GlycoMimetics
Pfizer
Novartis
Global Blood Therapeutics
Micelle BioPharma
Bluebird Bio
Prolong Pharmaceuticals
Modus Therapeutics
Sangamo Biosciences
Bioverativ
Imara
Ironwood Pharmaceuticals
Segment by Type
Blood Transfusion
Pharmacotherapy
Bone Marrow Transplant
Segment by Application
Child
Adult
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Sickle Cell Anemia Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Sickle Cell Anemia Therapeutics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Blood Transfusion
1.2.3 Pharmacotherapy
1.2.4 Bone Marrow Transplant
1.3 Market by Application
1.3.1 Global Sickle Cell Anemia Therapeutics Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Child
1.3.3 Adult
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Sickle Cell Anemia Therapeutics Market Perspective (2019-2030)
2.2 Sickle Cell Anemia Therapeutics Growth Trends by Region
2.2.1 Global Sickle Cell Anemia Therapeutics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Sickle Cell Anemia Therapeutics Historic Market Size by Region (2019-2024)
2.2.3 Sickle Cell Anemia Therapeutics Forecasted Market Size by Region (2025-2030)
2.3 Sickle Cell Anemia Therapeutics Market Dynamics
2.3.1 Sickle Cell Anemia Therapeutics Industry Trends
2.3.2 Sickle Cell Anemia Therapeutics Market Drivers
2.3.3 Sickle Cell Anemia Therapeutics Market Challenges
2.3.4 Sickle Cell Anemia Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Sickle Cell Anemia Therapeutics Players by Revenue
3.1.1 Global Top Sickle Cell Anemia Therapeutics Players by Revenue (2019-2024)
3.1.2 Global Sickle Cell Anemia Therapeutics Revenue Market Share by Players (2019-2024)
3.2 Global Sickle Cell Anemia Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Sickle Cell Anemia Therapeutics Revenue
3.4 Global Sickle Cell Anemia Therapeutics Market Concentration Ratio
3.4.1 Global Sickle Cell Anemia Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Sickle Cell Anemia Therapeutics Revenue in 2023
3.5 Sickle Cell Anemia Therapeutics Key Players Head office and Area Served
3.6 Key Players Sickle Cell Anemia Therapeutics Product Solution and Service
3.7 Date of Enter into Sickle Cell Anemia Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Sickle Cell Anemia Therapeutics Breakdown Data by Type
4.1 Global Sickle Cell Anemia Therapeutics Historic Market Size by Type (2019-2024)
4.2 Global Sickle Cell Anemia Therapeutics Forecasted Market Size by Type (2025-2030)
5 Sickle Cell Anemia Therapeutics Breakdown Data by Application
5.1 Global Sickle Cell Anemia Therapeutics Historic Market Size by Application (2019-2024)
5.2 Global Sickle Cell Anemia Therapeutics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Sickle Cell Anemia Therapeutics Market Size (2019-2030)
6.2 North America Sickle Cell Anemia Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Sickle Cell Anemia Therapeutics Market Size by Country (2019-2024)
6.4 North America Sickle Cell Anemia Therapeutics Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Sickle Cell Anemia Therapeutics Market Size (2019-2030)
7.2 Europe Sickle Cell Anemia Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Sickle Cell Anemia Therapeutics Market Size by Country (2019-2024)
7.4 Europe Sickle Cell Anemia Therapeutics Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Sickle Cell Anemia Therapeutics Market Size (2019-2030)
8.2 Asia-Pacific Sickle Cell Anemia Therapeutics Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Sickle Cell Anemia Therapeutics Market Size by Region (2019-2024)
8.4 Asia-Pacific Sickle Cell Anemia Therapeutics Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Sickle Cell Anemia Therapeutics Market Size (2019-2030)
9.2 Latin America Sickle Cell Anemia Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Sickle Cell Anemia Therapeutics Market Size by Country (2019-2024)
9.4 Latin America Sickle Cell Anemia Therapeutics Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Sickle Cell Anemia Therapeutics Market Size (2019-2030)
10.2 Middle East & Africa Sickle Cell Anemia Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Sickle Cell Anemia Therapeutics Market Size by Country (2019-2024)
10.4 Middle East & Africa Sickle Cell Anemia Therapeutics Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Emmaus Medical
11.1.1 Emmaus Medical Company Detail
11.1.2 Emmaus Medical Business Overview
11.1.3 Emmaus Medical Sickle Cell Anemia Therapeutics Introduction
11.1.4 Emmaus Medical Revenue in Sickle Cell Anemia Therapeutics Business (2019-2024)
11.1.5 Emmaus Medical Recent Development
11.2 Addmedica
11.2.1 Addmedica Company Detail
11.2.2 Addmedica Business Overview
11.2.3 Addmedica Sickle Cell Anemia Therapeutics Introduction
11.2.4 Addmedica Revenue in Sickle Cell Anemia Therapeutics Business (2019-2024)
11.2.5 Addmedica Recent Development
11.3 Gamida Cell
11.3.1 Gamida Cell Company Detail
11.3.2 Gamida Cell Business Overview
11.3.3 Gamida Cell Sickle Cell Anemia Therapeutics Introduction
11.3.4 Gamida Cell Revenue in Sickle Cell Anemia Therapeutics Business (2019-2024)
11.3.5 Gamida Cell Recent Development
11.4 GlycoMimetics
11.4.1 GlycoMimetics Company Detail
11.4.2 GlycoMimetics Business Overview
11.4.3 GlycoMimetics Sickle Cell Anemia Therapeutics Introduction
11.4.4 GlycoMimetics Revenue in Sickle Cell Anemia Therapeutics Business (2019-2024)
11.4.5 GlycoMimetics Recent Development
11.5 Pfizer
11.5.1 Pfizer Company Detail
11.5.2 Pfizer Business Overview
11.5.3 Pfizer Sickle Cell Anemia Therapeutics Introduction
11.5.4 Pfizer Revenue in Sickle Cell Anemia Therapeutics Business (2019-2024)
11.5.5 Pfizer Recent Development
11.6 Novartis
11.6.1 Novartis Company Detail
11.6.2 Novartis Business Overview
11.6.3 Novartis Sickle Cell Anemia Therapeutics Introduction
11.6.4 Novartis Revenue in Sickle Cell Anemia Therapeutics Business (2019-2024)
11.6.5 Novartis Recent Development
11.7 Global Blood Therapeutics
11.7.1 Global Blood Therapeutics Company Detail
11.7.2 Global Blood Therapeutics Business Overview
11.7.3 Global Blood Therapeutics Sickle Cell Anemia Therapeutics Introduction
11.7.4 Global Blood Therapeutics Revenue in Sickle Cell Anemia Therapeutics Business (2019-2024)
11.7.5 Global Blood Therapeutics Recent Development
11.8 Micelle BioPharma
11.8.1 Micelle BioPharma Company Detail
11.8.2 Micelle BioPharma Business Overview
11.8.3 Micelle BioPharma Sickle Cell Anemia Therapeutics Introduction
11.8.4 Micelle BioPharma Revenue in Sickle Cell Anemia Therapeutics Business (2019-2024)
11.8.5 Micelle BioPharma Recent Development
11.9 Bluebird Bio
11.9.1 Bluebird Bio Company Detail
11.9.2 Bluebird Bio Business Overview
11.9.3 Bluebird Bio Sickle Cell Anemia Therapeutics Introduction
11.9.4 Bluebird Bio Revenue in Sickle Cell Anemia Therapeutics Business (2019-2024)
11.9.5 Bluebird Bio Recent Development
11.10 Prolong Pharmaceuticals
11.10.1 Prolong Pharmaceuticals Company Detail
11.10.2 Prolong Pharmaceuticals Business Overview
11.10.3 Prolong Pharmaceuticals Sickle Cell Anemia Therapeutics Introduction
11.10.4 Prolong Pharmaceuticals Revenue in Sickle Cell Anemia Therapeutics Business (2019-2024)
11.10.5 Prolong Pharmaceuticals Recent Development
11.11 Modus Therapeutics
11.11.1 Modus Therapeutics Company Detail
11.11.2 Modus Therapeutics Business Overview
11.11.3 Modus Therapeutics Sickle Cell Anemia Therapeutics Introduction
11.11.4 Modus Therapeutics Revenue in Sickle Cell Anemia Therapeutics Business (2019-2024)
11.11.5 Modus Therapeutics Recent Development
11.12 Sangamo Biosciences
11.12.1 Sangamo Biosciences Company Detail
11.12.2 Sangamo Biosciences Business Overview
11.12.3 Sangamo Biosciences Sickle Cell Anemia Therapeutics Introduction
11.12.4 Sangamo Biosciences Revenue in Sickle Cell Anemia Therapeutics Business (2019-2024)
11.12.5 Sangamo Biosciences Recent Development
11.13 Bioverativ
11.13.1 Bioverativ Company Detail
11.13.2 Bioverativ Business Overview
11.13.3 Bioverativ Sickle Cell Anemia Therapeutics Introduction
11.13.4 Bioverativ Revenue in Sickle Cell Anemia Therapeutics Business (2019-2024)
11.13.5 Bioverativ Recent Development
11.14 Imara
11.14.1 Imara Company Detail
11.14.2 Imara Business Overview
11.14.3 Imara Sickle Cell Anemia Therapeutics Introduction
11.14.4 Imara Revenue in Sickle Cell Anemia Therapeutics Business (2019-2024)
11.14.5 Imara Recent Development
11.15 Ironwood Pharmaceuticals
11.15.1 Ironwood Pharmaceuticals Company Detail
11.15.2 Ironwood Pharmaceuticals Business Overview
11.15.3 Ironwood Pharmaceuticals Sickle Cell Anemia Therapeutics Introduction
11.15.4 Ironwood Pharmaceuticals Revenue in Sickle Cell Anemia Therapeutics Business (2019-2024)
11.15.5 Ironwood Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Sickle Cell Anemia Therapeutics Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Blood Transfusion
Table 3. Key Players of Pharmacotherapy
Table 4. Key Players of Bone Marrow Transplant
Table 5. Global Sickle Cell Anemia Therapeutics Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Sickle Cell Anemia Therapeutics Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global Sickle Cell Anemia Therapeutics Market Size by Region (2019-2024) & (US$ Million)
Table 8. Global Sickle Cell Anemia Therapeutics Market Share by Region (2019-2024)
Table 9. Global Sickle Cell Anemia Therapeutics Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 10. Global Sickle Cell Anemia Therapeutics Market Share by Region (2025-2030)
Table 11. Sickle Cell Anemia Therapeutics Market Trends
Table 12. Sickle Cell Anemia Therapeutics Market Drivers
Table 13. Sickle Cell Anemia Therapeutics Market Challenges
Table 14. Sickle Cell Anemia Therapeutics Market Restraints
Table 15. Global Sickle Cell Anemia Therapeutics Revenue by Players (2019-2024) & (US$ Million)
Table 16. Global Sickle Cell Anemia Therapeutics Market Share by Players (2019-2024)
Table 17. Global Top Sickle Cell Anemia Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Sickle Cell Anemia Therapeutics as of 2023)
Table 18. Ranking of Global Top Sickle Cell Anemia Therapeutics Companies by Revenue (US$ Million) in 2023
Table 19. Global 5 Largest Players Market Share by Sickle Cell Anemia Therapeutics Revenue (CR5 and HHI) & (2019-2024)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Sickle Cell Anemia Therapeutics Product Solution and Service
Table 22. Date of Enter into Sickle Cell Anemia Therapeutics Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Sickle Cell Anemia Therapeutics Market Size by Type (2019-2024) & (US$ Million)
Table 25. Global Sickle Cell Anemia Therapeutics Revenue Market Share by Type (2019-2024)
Table 26. Global Sickle Cell Anemia Therapeutics Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 27. Global Sickle Cell Anemia Therapeutics Revenue Market Share by Type (2025-2030)
Table 28. Global Sickle Cell Anemia Therapeutics Market Size by Application (2019-2024) & (US$ Million)
Table 29. Global Sickle Cell Anemia Therapeutics Revenue Market Share by Application (2019-2024)
Table 30. Global Sickle Cell Anemia Therapeutics Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 31. Global Sickle Cell Anemia Therapeutics Revenue Market Share by Application (2025-2030)
Table 32. North America Sickle Cell Anemia Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 33. North America Sickle Cell Anemia Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 34. North America Sickle Cell Anemia Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 35. Europe Sickle Cell Anemia Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 36. Europe Sickle Cell Anemia Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 37. Europe Sickle Cell Anemia Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 38. Asia-Pacific Sickle Cell Anemia Therapeutics Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 39. Asia-Pacific Sickle Cell Anemia Therapeutics Market Size by Region (2019-2024) & (US$ Million)
Table 40. Asia-Pacific Sickle Cell Anemia Therapeutics Market Size by Region (2025-2030) & (US$ Million)
Table 41. Latin America Sickle Cell Anemia Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 42. Latin America Sickle Cell Anemia Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 43. Latin America Sickle Cell Anemia Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 44. Middle East & Africa Sickle Cell Anemia Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 45. Middle East & Africa Sickle Cell Anemia Therapeutics Market Size by Country (2019-2024) & (US$ Million)
Table 46. Middle East & Africa Sickle Cell Anemia Therapeutics Market Size by Country (2025-2030) & (US$ Million)
Table 47. Emmaus Medical Company Detail
Table 48. Emmaus Medical Business Overview
Table 49. Emmaus Medical Sickle Cell Anemia Therapeutics Product
Table 50. Emmaus Medical Revenue in Sickle Cell Anemia Therapeutics Business (2019-2024) & (US$ Million)
Table 51. Emmaus Medical Recent Development
Table 52. Addmedica Company Detail
Table 53. Addmedica Business Overview
Table 54. Addmedica Sickle Cell Anemia Therapeutics Product
Table 55. Addmedica Revenue in Sickle Cell Anemia Therapeutics Business (2019-2024) & (US$ Million)
Table 56. Addmedica Recent Development
Table 57. Gamida Cell Company Detail
Table 58. Gamida Cell Business Overview
Table 59. Gamida Cell Sickle Cell Anemia Therapeutics Product
Table 60. Gamida Cell Revenue in Sickle Cell Anemia Therapeutics Business (2019-2024) & (US$ Million)
Table 61. Gamida Cell Recent Development
Table 62. GlycoMimetics Company Detail
Table 63. GlycoMimetics Business Overview
Table 64. GlycoMimetics Sickle Cell Anemia Therapeutics Product
Table 65. GlycoMimetics Revenue in Sickle Cell Anemia Therapeutics Business (2019-2024) & (US$ Million)
Table 66. GlycoMimetics Recent Development
Table 67. Pfizer Company Detail
Table 68. Pfizer Business Overview
Table 69. Pfizer Sickle Cell Anemia Therapeutics Product
Table 70. Pfizer Revenue in Sickle Cell Anemia Therapeutics Business (2019-2024) & (US$ Million)
Table 71. Pfizer Recent Development
Table 72. Novartis Company Detail
Table 73. Novartis Business Overview
Table 74. Novartis Sickle Cell Anemia Therapeutics Product
Table 75. Novartis Revenue in Sickle Cell Anemia Therapeutics Business (2019-2024) & (US$ Million)
Table 76. Novartis Recent Development
Table 77. Global Blood Therapeutics Company Detail
Table 78. Global Blood Therapeutics Business Overview
Table 79. Global Blood Therapeutics Sickle Cell Anemia Therapeutics Product
Table 80. Global Blood Therapeutics Revenue in Sickle Cell Anemia Therapeutics Business (2019-2024) & (US$ Million)
Table 81. Global Blood Therapeutics Recent Development
Table 82. Micelle BioPharma Company Detail
Table 83. Micelle BioPharma Business Overview
Table 84. Micelle BioPharma Sickle Cell Anemia Therapeutics Product
Table 85. Micelle BioPharma Revenue in Sickle Cell Anemia Therapeutics Business (2019-2024) & (US$ Million)
Table 86. Micelle BioPharma Recent Development
Table 87. Bluebird Bio Company Detail
Table 88. Bluebird Bio Business Overview
Table 89. Bluebird Bio Sickle Cell Anemia Therapeutics Product
Table 90. Bluebird Bio Revenue in Sickle Cell Anemia Therapeutics Business (2019-2024) & (US$ Million)
Table 91. Bluebird Bio Recent Development
Table 92. Prolong Pharmaceuticals Company Detail
Table 93. Prolong Pharmaceuticals Business Overview
Table 94. Prolong Pharmaceuticals Sickle Cell Anemia Therapeutics Product
Table 95. Prolong Pharmaceuticals Revenue in Sickle Cell Anemia Therapeutics Business (2019-2024) & (US$ Million)
Table 96. Prolong Pharmaceuticals Recent Development
Table 97. Modus Therapeutics Company Detail
Table 98. Modus Therapeutics Business Overview
Table 99. Modus Therapeutics Sickle Cell Anemia Therapeutics Product
Table 100. Modus Therapeutics Revenue in Sickle Cell Anemia Therapeutics Business (2019-2024) & (US$ Million)
Table 101. Modus Therapeutics Recent Development
Table 102. Sangamo Biosciences Company Detail
Table 103. Sangamo Biosciences Business Overview
Table 104. Sangamo Biosciences Sickle Cell Anemia Therapeutics Product
Table 105. Sangamo Biosciences Revenue in Sickle Cell Anemia Therapeutics Business (2019-2024) & (US$ Million)
Table 106. Sangamo Biosciences Recent Development
Table 107. Bioverativ Company Detail
Table 108. Bioverativ Business Overview
Table 109. Bioverativ Sickle Cell Anemia Therapeutics Product
Table 110. Bioverativ Revenue in Sickle Cell Anemia Therapeutics Business (2019-2024) & (US$ Million)
Table 111. Bioverativ Recent Development
Table 112. Imara Company Detail
Table 113. Imara Business Overview
Table 114. Imara Sickle Cell Anemia Therapeutics Product
Table 115. Imara Revenue in Sickle Cell Anemia Therapeutics Business (2019-2024) & (US$ Million)
Table 116. Imara Recent Development
Table 117. Ironwood Pharmaceuticals Company Detail
Table 118. Ironwood Pharmaceuticals Business Overview
Table 119. Ironwood Pharmaceuticals Sickle Cell Anemia Therapeutics Product
Table 120. Ironwood Pharmaceuticals Revenue in Sickle Cell Anemia Therapeutics Business (2019-2024) & (US$ Million)
Table 121. Ironwood Pharmaceuticals Recent Development
Table 122. Research Programs/Design for This Report
Table 123. Key Data Information from Secondary Sources
Table 124. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Sickle Cell Anemia Therapeutics Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Sickle Cell Anemia Therapeutics Market Share by Type: 2023 VS 2030
Figure 3. Blood Transfusion Features
Figure 4. Pharmacotherapy Features
Figure 5. Bone Marrow Transplant Features
Figure 6. Global Sickle Cell Anemia Therapeutics Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 7. Global Sickle Cell Anemia Therapeutics Market Share by Application: 2023 VS 2030
Figure 8. Child Case Studies
Figure 9. Adult Case Studies
Figure 10. Sickle Cell Anemia Therapeutics Report Years Considered
Figure 11. Global Sickle Cell Anemia Therapeutics Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 12. Global Sickle Cell Anemia Therapeutics Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 13. Global Sickle Cell Anemia Therapeutics Market Share by Region: 2023 VS 2030
Figure 14. Global Sickle Cell Anemia Therapeutics Market Share by Players in 2023
Figure 15. Global Top Sickle Cell Anemia Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Sickle Cell Anemia Therapeutics as of 2023)
Figure 16. The Top 10 and 5 Players Market Share by Sickle Cell Anemia Therapeutics Revenue in 2023
Figure 17. North America Sickle Cell Anemia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 18. North America Sickle Cell Anemia Therapeutics Market Share by Country (2019-2030)
Figure 19. United States Sickle Cell Anemia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 20. Canada Sickle Cell Anemia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. Europe Sickle Cell Anemia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Europe Sickle Cell Anemia Therapeutics Market Share by Country (2019-2030)
Figure 23. Germany Sickle Cell Anemia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. France Sickle Cell Anemia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. U.K. Sickle Cell Anemia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. Italy Sickle Cell Anemia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Russia Sickle Cell Anemia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Nordic Countries Sickle Cell Anemia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Asia-Pacific Sickle Cell Anemia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Asia-Pacific Sickle Cell Anemia Therapeutics Market Share by Region (2019-2030)
Figure 31. China Sickle Cell Anemia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Japan Sickle Cell Anemia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. South Korea Sickle Cell Anemia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Southeast Asia Sickle Cell Anemia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. India Sickle Cell Anemia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Australia Sickle Cell Anemia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Latin America Sickle Cell Anemia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Latin America Sickle Cell Anemia Therapeutics Market Share by Country (2019-2030)
Figure 39. Mexico Sickle Cell Anemia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Brazil Sickle Cell Anemia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Middle East & Africa Sickle Cell Anemia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Middle East & Africa Sickle Cell Anemia Therapeutics Market Share by Country (2019-2030)
Figure 43. Turkey Sickle Cell Anemia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Saudi Arabia Sickle Cell Anemia Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Emmaus Medical Revenue Growth Rate in Sickle Cell Anemia Therapeutics Business (2019-2024)
Figure 46. Addmedica Revenue Growth Rate in Sickle Cell Anemia Therapeutics Business (2019-2024)
Figure 47. Gamida Cell Revenue Growth Rate in Sickle Cell Anemia Therapeutics Business (2019-2024)
Figure 48. GlycoMimetics Revenue Growth Rate in Sickle Cell Anemia Therapeutics Business (2019-2024)
Figure 49. Pfizer Revenue Growth Rate in Sickle Cell Anemia Therapeutics Business (2019-2024)
Figure 50. Novartis Revenue Growth Rate in Sickle Cell Anemia Therapeutics Business (2019-2024)
Figure 51. Global Blood Therapeutics Revenue Growth Rate in Sickle Cell Anemia Therapeutics Business (2019-2024)
Figure 52. Micelle BioPharma Revenue Growth Rate in Sickle Cell Anemia Therapeutics Business (2019-2024)
Figure 53. Bluebird Bio Revenue Growth Rate in Sickle Cell Anemia Therapeutics Business (2019-2024)
Figure 54. Prolong Pharmaceuticals Revenue Growth Rate in Sickle Cell Anemia Therapeutics Business (2019-2024)
Figure 55. Modus Therapeutics Revenue Growth Rate in Sickle Cell Anemia Therapeutics Business (2019-2024)
Figure 56. Sangamo Biosciences Revenue Growth Rate in Sickle Cell Anemia Therapeutics Business (2019-2024)
Figure 57. Bioverativ Revenue Growth Rate in Sickle Cell Anemia Therapeutics Business (2019-2024)
Figure 58. Imara Revenue Growth Rate in Sickle Cell Anemia Therapeutics Business (2019-2024)
Figure 59. Ironwood Pharmaceuticals Revenue Growth Rate in Sickle Cell Anemia Therapeutics Business (2019-2024)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
